• Abstract Submission
    Abstract Submission
    Abstract submission will open September 1,  2016
  • Exhibitor & Support Opportunities
    Exhibitor & Support Opportunities
    Act now to identify the best strategies at TAT 2017 to get the RESULTS your company expects in this dynamic marketplace.
  • Registration
    Registration
    Registration will open September 1, 2016
  • Phase 1: the revolution is ongoing!
    Phase 1: the revolution is ongoing!
    A revolution is ongoing, which has already changed and will continue to change the role of phase 1 studies in oncology drug development.
  • Meet global phase 1 leaders
    Meet global phase 1 leaders
    Expand your network with global leaders in early-phase drug development at TAT 2017. Many leading phase 1 investigators and translational research scientists are confirmed speakers or session chairs.
  • TAT 2016 report
    TAT 2016 report
    A brief report of TAT 2016 is online now. Over the three days of the conference, 45 oral presentations covered 23 unique new drugs or drug classes in early-phase clinical trials at the time of the conference.